Straits Times Index
3,187.66 +32.97 (+1.05%) S&P 500
5,039.04 +16.83 (+0.34%) Dow
37,930.30 +176.99 (+0.47%) Nasdaq
15,729.14 +45.77 (+0.29%) Bitcoin USD
63,394.20 +2,543.34 (+4.18%) CMC Crypto 200
885.54 0.00 (0.00%)
VRTX Jun 2024 340.000 call
| Previous close | 80.90 |
| Open | 80.90 |
| Bid | 56.40 |
| Ask | 62.00 |
| Strike | 340.00 |
| Expiry date | 2024-06-21 |
| Day's range | 80.90 - 80.90 |
| Contract range | N/A |
| Volume | |
| Open interest | 162 |
Business WireVertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
BOSTON, April 18, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and neuropathic pain in more than two decades. Suzetrigine is an oral selective NaV1.8 pain signal inhibitor (formerly known as VX-548).
ZacksVertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
Vertex Pharmaceuticals (VRTX) closed at $394.17 in the latest trading session, marking a -0.8% move from the prior day.
Associated Press FinanceVertex Pharma scientist talks about the long road to developing non-addictive painkillers
For decades, patients seeking medication for pain have had two choices: over-the-counter drugs like aspirin or powerful prescription opioids like oxycodone. Opioid prescriptions have plummeted over the last decade as doctors have become more attuned to the risks of addiction and misuse during the country’s ongoing drug epidemic. Vertex Pharmaceuticals recently reported positive results for a non-opioid painkiller, one of several medications the Boston-based drugmaker has been developing for various forms of pain.
